Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

Recruiting now · Early Phase 1

Conditions studied: Toxic Epidermal Necrolysis

In brief

To evaluate the efficacy and safety of methylprednisolone combined with the JAK inhibitor abxitinib and tofacitinib in the treatment of toxic epidermal necrolysis

Key facts

Study ID

NCT06119490

Run by

Peng Zhang

People needed

30

Starts

2023-07-05

Expected to finish

2026-09-01

Last updated by the study team

2023-11-28

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 and above.
• Diagnosed with SJS/TEN according to the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) criteria.
• Liver and kidney function is within acceptable ranges.
• Blood parameters, including complete blood count, coagulation function, and platelet count, are within acceptable ranges.
• Patients must sign an informed consent form, understanding the risks and potential benefits of the treatment.
• Patients need to be capable of participating in follow-up visits and treatment plans.

You may not qualify if…

• History of allergy to JAK inhibitors.
• Pregnant or breastfeeding women.
• Severe infectious conditions.
• History of central nervous system demyelinating diseases.
• History of lymphoproliferative diseases.
• Active and latent tuberculosis.
• HIV carriers with a CD4+ T cell count lower than (<200/mL).
• Active HBV/HCV infection.
• Coagulation disorders or a tendency for thrombosis.
• Significant abnormalities in blood routine indicators.
• Liver or kidney dysfunction.

Where it is running

• Department of Dermatology, the First Affiliated Hospital of Fujian Medical University. — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.